3.385USD-3.29%Mkt Cap: 43.57M USDP/E: —Last update: 2026-05-26
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small ce…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap43.57M USD
Enterprise Value31.27M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-17.12M USD
Revenue/Share—
Last Price3.385 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees16
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.64
PEG—
EV/EBITDA-1.88
EV/Revenue—
P/S—
P/B5.71
EPS (TTM)-1.45
EPS (Forward)-2.02
52W Range
1.11049% of range5.744
52W High5.744 USD
52W Low1.110 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-262.00%
ROA-155.13%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.68M USD
CapEx (TTM)1.72K USD
FCF Margin—
FCF Yield-21.03%
Net Debt-6.26M USD
Net Debt/EBITDA0.38
Balance Sheet
Debt/Equity0.01
Current Ratio1.87
Quick Ratio1.67
Book Value/Sh0.5810 USD
Cash/Share0.5590 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)20.00 USD
Target Range15.00 USD – 25.00 USD
# Analysts2
Ownership
Shares Out.12.76M
Float8.61M
Insiders17.15%
Institutions14.23%
Short Interest
Short Ratio1.7d
Short % Float17.90%
Short % Out.17.83%
Shares Short2.02M
Short (prev mo.)2.19M
Technical
SMA 502.257 (+50.0%)
SMA 2003.305 (+2.4%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)307.94K
Avg Vol (10d)422.35K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—